Invesco Pharmaceuticals ETF (PJP)
| Assets | $265.17M |
| Expense Ratio | 0.56% |
| PE Ratio | 24.72 |
| Shares Out | 3.22M |
| Dividend (ttm) | $0.77 |
| Dividend Yield | 0.93% |
| Ex-Dividend Date | Sep 23, 2024 |
| Payout Ratio | 23.05% |
| 1-Year Return | +10.41% |
| Volume | 8,023 |
| Open | 82.39 |
| Previous Close | 82.36 |
| Day's Range | 82.39 - 83.54 |
| 52-Week Low | 74.82 |
| 52-Week High | 89.87 |
| Beta | 0.57 |
| Holdings | 34 |
| Inception Date | Jun 23, 2005 |
About PJP
Fund Home PageThe Invesco Pharmaceuticals ETF (PJP) is an exchange-traded fund that mostly invests in health care equity. The fund tracks an index of US pharmaceutical companies selected and weighted based on various factors using a quantitative methodology. PJP was launched on Jun 23, 2005 and is issued by Invesco.
Top 10 Holdings
46.19% of assets| Name | Symbol | Weight |
|---|---|---|
| Eli Lilly and Company | LLY | 5.27% |
| Pfizer Inc. | PFE | 5.17% |
| Merck & Co., Inc. | MRK | 5.17% |
| AbbVie Inc. | ABBV | 5.09% |
| Bristol-Myers Squibb Company | BMY | 5.03% |
| Abbott Laboratories | ABT | 5.00% |
| Johnson & Johnson | JNJ | 4.84% |
| Amgen Inc. | AMGN | 4.67% |
| Tarsus Pharmaceuticals, Inc. | TARS | 3.08% |
| Gilead Sciences, Inc. | GILD | 2.88% |
Dividends
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Sep 23, 2024 | $0.200 | Sep 27, 2024 |
| Jun 24, 2024 | $0.210 | Jun 28, 2024 |
| Mar 18, 2024 | $0.170 | Mar 22, 2024 |
| Dec 18, 2023 | $0.191 | Dec 22, 2023 |
| Sep 18, 2023 | $0.201 | Sep 22, 2023 |
| Jun 20, 2023 | $0.176 | Jun 23, 2023 |
News
PJP: A Dynamic Pharma Fund
Bullish on pharmaceuticals and health care due to relative momentum and preference for "need" sectors over cyclical ones. The Invesco Pharmaceuticals ETF provides exposure to select pharmaceutical sto...
PJP: Pharma Investing Is Difficult And This Fund Doesn't Make It Easier
Invesco Dynamic Pharmaceuticals ETF is a passively managed fund that tracks the Dynamic Pharmaceutical Intellidex Index. Investing in the pharmaceutical industry is challenging due to the need for spe...
PJP: Concentrating On Large-Cap Biopharmaceuticals Seems To Be A Bad Strategy
55 percent of Invesco Dynamic Pharmaceuticals ETF's investment is in ten giant-capitalized and large-capitalized biopharmaceutical stocks which delivered poor returns over the long run. 18 blockbuster...
Subversive Launches ETF to Focus on Mental Health
The debut highlights the lack of funds focused on the area.
What The Inflation Reduction Act Means For Drug Prices
The recently enacted Inflation Reduction Act looks to rein in prescription drug prices and could impact the pharma industry's long-term financial performance. The legislation caps out-of-pocket costs ...
Biotech Innovations Remain At Forefront
The first quarter of 2021 was challenging for the biotechnology industry, as the selloff in March represented a sharp reversal from record highs in February. While the sector has remained relatively r...
Moving Beyond COVID In Biopharma
Just over one year after COVID-19 disrupted our lives, we are now getting to the point where multiple vaccine options are nearly ubiquitous for those in the United States. Per the CDC, as of April 12,...
Healthcare: A Wide Choice Of Large And Well-Established Companies
The advantage for dividend investors in this sector is the wide choice of large and well-established companies. AbbVie is a drug company with strong exposure to the immunology and the oncology markets...
Best Pharmaceutical ETFs for Q4 2020
The best pharmaceutical ETFs for Q4 2020 are KURE, XPH, and PJP.
